Berry Consultants will prominently participate in the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop in Washington, D.C. from September 12-14, 2018, with team members Scott Berry, Melanie Quintana, and Tom Parke presenting on various innovative topics related to clinical trial designs.

Berry Consultants will sponsor the Joint Statistical Meetings in Vancouver from July 28 to August 2, showcasing their new software FACTS 6.2 and QUOTES at exhibit booth #324, while also participating in various sessions throughout the event.

Hierarchical modeling is an advanced statistical approach used in clinical trials to make inferences across multiple patient groups, enhancing power and reducing sample sizes while requiring careful implementation to account for variability and potential biases in observed data.

Berry Consultants is excited to announce the release of FACTS 6.1, which introduces new Dose Escalation simulation types, enhanced functionality with 'Design Variants' across all FACTS engines, and maintains full compatibility with previous versions, making it easier to estimate sample sizes and analyze trial outcomes.

This week, we published an article in JAMA titled “Bayesian Analysis: Use of Prior Information in Clinical Trials,” which explores the nuances of Bayesian analysis in clinical trials, emphasizing the importance of transparency and community consensus when using informative priors to avoid bias and enhance trial efficiency.

Berry Consultants has launched a Clinical Trial Strategy Team, led by Dr. Meredith Buxton and Dr. Melissa Paoloni, to enhance the design and implementation of innovative platform and adaptive clinical trials across all therapeutic areas, aiming to advance precision medicine through expert guidance and comprehensive services.